isoxazoles has been researched along with Neoplasms in 63 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (11.11) | 18.7374 |
1990's | 6 (9.52) | 18.2507 |
2000's | 8 (12.70) | 29.6817 |
2010's | 35 (55.56) | 24.3611 |
2020's | 7 (11.11) | 2.80 |
Authors | Studies |
---|---|
Fang, X; Feng, J; Luan, Y; Wang, K | 1 |
Guzhova, I; Margulis, B; Mikhaylova, E; Multhoff, G; Shevtsov, M; Shibata, A | 1 |
Alexander, M; Dines-Muntaner, S; Fullerton, S; Thakerar, A; Trifunovich, T | 1 |
Angeli, A; Carradori, S; Cirilli, R; D'Ascenzio, M; Guglielmi, P; Pierini, M; Poli, G; Secci, D; Supuran, CT; Tuccinardi, T; Zara, S | 1 |
Andrs, M; Gorecki, L; Korabecny, J; Rezacova, M | 1 |
Conlon, IL; Drennen, B; Fletcher, S; Hughes, S; Lanning, ME; MacKerell, AD; Rothhaas, R; Wilder, PT | 1 |
Aoshiba, K; Kawagoe, J; Kikuchi, R; Koyama, N; Maeda, Y; Nakamura, H; Tsuji, T; Yamaguchi, K | 1 |
Falk, M; Hendriks, BS; Jansen, M; Terranova, N | 1 |
Benites, J; Buc Calderon, P; Muccioli, GG; Ramos, M; Valderrama, JA | 1 |
Chen, Z; Li, L; Li, S; Yang, Y; Zhang, L | 1 |
Chu, M; Zhang, C | 1 |
Cheng, C; Jia, Y; Jin, X; Liu, Y; Wang, G; Yao, L; Zhang, J; Zhou, F | 1 |
Chen, Y; Lin, HZ; Mo, J; Sun, HP; Zhu, J | 1 |
Fernandez-Capetillo, O; Lecona, E | 1 |
Behera, M; Hota, PK; Kotla, SR; Kumar, PR; Penugurti, V; Raghavulu, K; Shree, AJ; Velatooru, LR; Yennam, S | 1 |
Akimov, M; Bailey, S; Banerji, U; Bhalla, KN; Britten, C; Chica, S; Fernandez-Ibarra, C; Jacks, KS; Lu, H; Mita, M; Papadimitrakopoulou, V; Pluard, T; Quadt, C; Samuel, TA; Sessa, C; Shapiro, GI | 1 |
Ge, D; Lambrechts, MJ; Li, Q; Liu, S; Xi, M; Yin, R; You, Z; Zhang, Q | 1 |
Bartzatt, R | 1 |
Kloog, Y; Rak, R | 1 |
Ding, Y; Shen, Q; Wild, C; Ye, N; Zhou, J | 1 |
Astin, JW; Chien, A; Crosier, KE; Crosier, PS; Eng, TC; Flores, MV; Jamieson, SM; Misa, JP | 1 |
Akimov, M; Boku, N; Doi, T; Fuse, N; Ohtsu, A; Onozawa, Y; Robson, M; Watanabe, J; Yamazaki, K; Yoshino, T | 1 |
Bayer, C; Konrad, S; Kühnel, A; Multhoff, G; Schilling, D; Tetzlaff, F; Yaglom, J | 1 |
Badr, JM; Khedr, A; Shaala, LA; Sulaiman, M; Youssef, DT | 1 |
Foote, KM; Lau, A; Nissink, JW | 1 |
An, H; Beauchamp, RD; Deane, NG; Lindsley, CW; Stoops, SL; Waterson, AG; Weaver, C; Zhu, J; Zi, J; Zijlstra, A | 1 |
Bendell, JC; Earwood, C; Hart, L; Infante, JR; Jones, SF; Lane, CM; Moyhuddin, A; Murphy, P; Pant, S; Patton, J; Penley, WC; Thompson, D | 1 |
Kim, ND; Lee, KB; Nam, Y; Shin, I; Sim, T; Yoon, H | 1 |
Murali, K; Rajendra Prasad, KJ; Sparkes, HA | 1 |
Bansal, N; Bertino, JR; Birge, RB; Comollo, T; Kholodovych, V; Kimani, SG; Kotenko, SV; Kumar, S; Peng, Y; Sarafianos, SG; Singh, K; Welsh, WJ | 1 |
Bergström, M; Blomqvist, C; Ide, S; Josephsson, R; Langström, B; Monazzam, A; Razifar, P; Rugaard Jensen, M | 1 |
de Jong, JR; de Korte, MA; de Vries, EG; den Dunnen, WF; Garcia-Echeverria, C; Hollema, H; Jensen, MR; Lub-de Hooge, MN; Nagengast, WB; Oude Munnink, TH; Quadt, C; Schröder, CP; Timmer-Bosscha, H; van Dongen, GA | 1 |
Barraja, P; Carbone, A; Cirrincione, G; Diana, P; Fiebig, HH; Kelter, G | 1 |
Chatterjee, M; Djuzenova, CS; Flentje, M; Jensen, MR; Stingl, L; Stühmer, T | 1 |
Perrone, MG; Scilimati, A; Simone, L; Vitale, P | 1 |
Du, J; Liu, H; Qin, J; Yang, Y; Yao, X | 1 |
Behrens, F; Burkhardt, H; Koehm, M | 1 |
Nagi Reddy, M; Rajanarendar, E; Rama Murthy, K; Reddy, RN; Reddy, YN; Surendar, P | 1 |
Kiran, LH; Krishna, SR; Narasimha Reddy, AR; Rajanarendar, E; Raju, S; Reddy, MN; Reddy, YN | 1 |
Abo-Salem, HM; El-Sawy, ER; Islam, IE; Mahmoud, K; Mandour, AH | 1 |
Barsoum, J; Borella, C; Foley, KP; Jiang, J; Korbut, T; Li, H; Sang, J; Sonderfan, AJ; Wu, Y; Ye, J; Zhang, M; Zhang, X; Zhou, D | 1 |
Dadmal, TL; Janaki Ramaiah, M; Kosurkar, UB; Kumbhare, RM; Pal-Bhadra, M; Pushpavalli, SN | 1 |
Brumby, AM; Humbert, PO; Manning, SA; Parisot, JP; Richardson, HE; Schlosser, T; Street, IP; Willoughby, LF | 1 |
Aszalos, A; Cardarelli, C; Forte, R; Gottesman, MM; Kozar, M; Liang, XJ; Taylor, B; Wang, PC; Yin, JJ; Zhou, JW | 1 |
Aoki, J; Arai, H; Chun, J; Fukaya, M; Hama, K; Kishi, Y; Ohta, H; Sakai, T; Suzuki, R; Watanabe, M; Yamori, T | 1 |
Vanchieri, C | 1 |
Han, DC; Koh, S; Kwon, BM; Lee, MY; Lee, S; Paik, YK; Shin, DS; Shin, KD; Son, KH | 1 |
Bichat, F; Fujiwara, Y; Guilbaud, N; Hasegawa, K; Isae, T; Kubo, K; Miura, T; Nakamura, K; Shibuya, M; Suzuki, R; Taguchi, E; Takahashi, K; Yamamoto, A | 1 |
Chen, J; Fang, X; Gibson, SB; Graham, BA; Hu, X; Ishdorj, G; Johnston, JB | 1 |
Weber, G | 1 |
Alonso, MT; Leyland-Jones, B; O'Dwyer, PJ | 1 |
Belt, RJ; Haas, CD; Hoogstraten, B; Joseph, U; Taylor, S | 1 |
Kjaer, M; Nielsen, H | 1 |
Bruno, S; McGovren, JP; Neil, GL; Penta, J; Poster, DS | 1 |
Kufe, DW; McGovren, JP; Schade, D; Weiss, GR | 1 |
Souba, WW | 1 |
Baruchel, S; Bell, B; Bernstein, M; Devine, S; Dubowy, R; Grier, H; Kretschmar, C; Langevin, AM; Vietti, T; Whitehead, VM | 1 |
Daniels, DL; Debnath, ML; Hall, IH; Izydore, RA; Muhammad, RA; Tse, E; Woodard, T; Zhou, X | 1 |
Brown, T; Hidalgo, M; Kuhn, JG; MacGovren, JP; Rodriguez, G; Rowinsky, EK; Von Hoff, DD; Weiss, G | 1 |
Hudes, G | 1 |
Baker, SD; Cropp, G; Drengler, R; Eckardt, JR; Eckhardt, SG; Hammond, L; Hannah, AL; Kraynak, MA; Kuhn, JG; Moczygemba, J; Rizzo, J; Rowinsky, EK; Smith, L; Sweeney, KR; Thurman, A; Villalona-Calero, MA; Von Hoff, DD; Weiss, G | 1 |
Doi, H; Komatsu, H; Nishihira, T; Satomi, S | 1 |
Alberti, D; Bruggink, J; Earhart, RH; Fischer, PH; Hamilton, RD; Koeller, JM; Simon, K; Tormey, DC; Tutsch, K; Willson, JK | 1 |
12 review(s) available for isoxazoles and Neoplasms
Article | Year |
---|---|
Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Molecular Chaperones; Neoplasms; Oligonucleotides; Resorcinols | 2019 |
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Drug Discovery; Drug Synergism; Humans; Isoxazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sulfones; Treatment Outcome | 2020 |
Leflunomide: A promising drug with good antitumor potential.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Enzyme Inhibitors; Humans; Immunologic Factors; Isoxazoles; Leflunomide; Neoplasms; Neoplastic Stem Cells | 2018 |
The recent progress of isoxazole in medicinal chemistry.
Topics: Anti-Infective Agents; Antineoplastic Agents; Bacteria; Cell Survival; Chemistry, Pharmaceutical; Fungi; Humans; Isoxazoles; Neoplasms; RNA Viruses | 2018 |
Targeting ATR in cancer.
Topics: Ataxia Telangiectasia Mutated Proteins; DNA Damage; Drug Development; Genomic Instability; Humans; Indoles; Isoxazoles; Molecular Targeted Therapy; Morpholines; Neoplasms; Nitroso Compounds; Oxazines; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinolines; Sulfonamides; Sulfoxides | 2018 |
Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; DNA Damage; Humans; Isoxazoles; Molecular Conformation; Neoplasms; Pyrazines | 2015 |
Selective COX-1 inhibition: A therapeutic target to be reconsidered.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Endothelial Cells; Female; Humans; Isoxazoles; Neoplasms; Nervous System Diseases; Obstetric Labor, Premature; Pain; Pregnancy | 2010 |
Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
Topics: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Intercellular Adhesion Molecule-1; Isoxazoles; Leflunomide; Liver; Lung Diseases; Lymphocyte Function-Associated Antigen-1; Methotrexate; Neoplasms; Pharmacogenetics; Rituximab; Tumor Necrosis Factor-alpha | 2011 |
Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.
Topics: Adenosine Monophosphate; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Deoxyribonucleotides; Gene Expression Regulation; Gluconeogenesis; Guanosine Monophosphate; Humans; Inosine Monophosphate; Isoxazoles; Kidney Neoplasms; Liver Neoplasms; Liver Regeneration; Models, Biological; Neoplasms; Purines; Pyrimidines; Ribonucleotides | 1983 |
Acivicin. An antitumor antibiotic.
Topics: Animals; Antibiotics, Antineoplastic; Glycine; Humans; Isoxazoles; Neoplasms; Neoplasms, Experimental; Oxazoles | 1981 |
Glutamine and cancer.
Topics: Antimetabolites, Antineoplastic; Cell Division; Diazooxonorleucine; Glutamine; Humans; Intestinal Mucosa; Intestines; Isoxazoles; Lymphocytes; Muscles; Neoplasms; Parenteral Nutrition, Total; Randomized Controlled Trials as Topic | 1993 |
[Anti-cancer therapy with amino acid imbalance].
Topics: Amino Acids; Antimetabolites, Antineoplastic; Arginine; Asparagine; Glutamine; Humans; Isoxazoles; Methionine; Neoplasms; Valine | 2001 |
7 trial(s) available for isoxazoles and Neoplasms
Article | Year |
---|---|
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Isoxazoles; Male; Middle Aged; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Pyrazines | 2021 |
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Resorcinols; Treatment Outcome | 2013 |
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.
Topics: Antineoplastic Agents; Asian People; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Resorcinols; Treatment Outcome | 2014 |
A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Capecitabine; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Middle Aged; Neoplasms; Resorcinols | 2015 |
A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Drug Resistance, Neoplasm; Enzyme Inhibitors; gamma-Glutamyltransferase; Humans; Injections, Intravenous; Isoxazoles; Neoplasms; Tumor Cells, Cultured | 1995 |
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Topics: Adult; Aged; Amino Acids; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Electrolytes; Female; Glucose; Glutamine; Humans; Isoxazoles; Male; Middle Aged; Neoplasms; Parenteral Nutrition Solutions; Solutions; Thrombocytopenia; Treatment Outcome | 1998 |
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Growth Inhibitors; Humans; Immunohistochemistry; Infusions, Intravenous; Isoxazoles; Leflunomide; Male; Middle Aged; Neoplasms; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors | 1999 |
44 other study(ies) available for isoxazoles and Neoplasms
Article | Year |
---|---|
Development of VER-50589 analogs as novel Hsp90 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Neoplasms | 2023 |
Parecoxib as an adjunct therapy for the treatment of refractory non-surgical cancer pain.
Topics: Adult; Aged; Aged, 80 and over; Australia; Cancer Pain; Cohort Studies; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Middle Aged; Neoplasms; Pain Measurement; Retrospective Studies; Young Adult | 2020 |
1,3-Dipolar Cycloaddition, HPLC Enantioseparation, and Docking Studies of Saccharin/Isoxazole and Saccharin/Isoxazoline Derivatives as Selective Carbonic Anhydrase IX and XII Inhibitors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Line; Cycloaddition Reaction; Humans; Isoxazoles; MCF-7 Cells; Molecular Docking Simulation; Neoplasms; Saccharin | 2020 |
Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Design; Humans; Isoxazoles; Molecular Structure; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Protein Binding; Protein Conformation, alpha-Helical; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Structure-Activity Relationship; Thiazoles | 2020 |
Anti-cancer strategy targeting the energy metabolism of tumor cells surviving a low-nutrient acidic microenvironment.
Topics: Acidosis; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Energy Metabolism; Gene Expression Regulation, Neoplastic; Glucose; Humans; Hydrazones; Isoxazoles; Mitochondria; Neoplasms; Tumor Microenvironment | 2020 |
Targeting Akt as strategy to kill cancer cells using 3-substituted 5-anilinobenzo[c]isoxazolequinones: A preliminary study.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line; Cell Line, Tumor; Fibroblasts; Glutathione; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Isoxazoles; Neoplasms; Proto-Oncogene Proteins c-akt; Quinones; Structure-Activity Relationship | 2018 |
COX‑2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression.
Topics: Animals; Antineoplastic Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Endothelial Cells; Female; Glucose; Glycolysis; Isoxazoles; Mice, Inbred C57BL; Neoplasms; Ovarian Neoplasms; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2018 |
Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 Enzyme System; Drug Monitoring; Female; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Neoplasms; Oxazoles; Prodrugs; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2018 |
Synthesis of Novel Diaziridinyl Quinone Isoxazole Hybrids and Evaluation of Their Anti-Cancer Activity as Potential Tubulin-Targeting Agents.
Topics: Antineoplastic Agents; Azirines; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Inhibitory Concentration 50; Isoxazoles; Neoplasms; Quinones; Toxicity Tests; Tubulin; Tubulin Modulators | 2019 |
Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis.
Topics: Apoptosis; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epithelial Cells; Female; Glycine; Glyphosate; Humans; Isoxazoles; Male; Neoplasms; Organophosphonates; Prostate; Tetrazoles; Up-Regulation | 2013 |
Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Design; Humans; Isoxazoles; Models, Molecular; Neoplasms; Pain; Sulfonamides | 2014 |
Targeting LIM kinase in cancer and neurofibromatosis.
Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Isoxazoles; Lim Kinases; Mice; Neoplasms; Neurofibromatosis 1 | 2014 |
Small molecule inhibitors targeting activator protein 1 (AP-1).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Benzophenones; Biological Products; Humans; Inflammation; Isoxazoles; Maleimides; Molecular Targeted Therapy; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction; Small Molecule Libraries; Transcription Factor AP-1; Transcription Factors | 2014 |
An in vivo antilymphatic screen in zebrafish identifies novel inhibitors of mammalian lymphangiogenesis and lymphatic-mediated metastasis.
Topics: Animals; Antineoplastic Agents; Cinnarizine; Endothelial Cells; Female; Flunarizine; Humans; Isoxazoles; Kaempferols; Leflunomide; Lymph Nodes; Lymphangiogenesis; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Neoplasms; Random Allocation; Receptor Protein-Tyrosine Kinases; Zebrafish | 2014 |
Sensitizing tumor cells to radiation by targeting the heat shock response.
Topics: Cell Line, Tumor; Cell Movement; DNA-Binding Proteins; Fibroblasts; Heat Shock Transcription Factors; Heat-Shock Response; HSP70 Heat-Shock Proteins; Humans; Isoxazoles; Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols; Transcription Factors | 2015 |
Bioactive secondary metabolites from the Red Sea marine Verongid sponge Suberea species.
Topics: Alkaloids; Animals; Antineoplastic Agents; Benzofurans; Bromobenzenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Discovery; Egypt; Humans; Hydrocarbons, Brominated; Hydroquinones; Isoxazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Neoplasms; Oceans and Seas; Porifera; Saudi Arabia; Secondary Metabolism; Spectrometry, Mass, Electrospray Ionization; Spiro Compounds; Stereoisomerism | 2015 |
Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition.
Topics: Animals; Cadherins; Cell Line, Tumor; Chick Embryo; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Female; Humans; Isoxazoles; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neoplasm Invasiveness; Neoplasms; Niacinamide; Small Molecule Libraries; Transcription, Genetic | 2015 |
Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Humans; Isoxazoles; Mice; Models, Molecular; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles | 2017 |
Synthesis of hetero annulated isoxazolo-, pyrido- and pyrimido carbazoles: Screened for in vitro antitumor activity and structure activity relationships, a novel 2-amino-4-(3'-bromo-4'-methoxyphenyl)-8-chloro-11H-pyrimido[4,5-a]carbazole as an antitumor a
Topics: Antineoplastic Agents; Carbazoles; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Isoxazoles; Molecular Structure; Neoplasms; Pyridones; Pyrimidines; Pyrimidinones; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
Topics: Animals; Axl Receptor Tyrosine Kinase; Binding Sites; Body Weight; c-Mer Tyrosine Kinase; Carcinogenesis; Cell Line, Tumor; Humans; Intercellular Signaling Peptides and Proteins; Isoxazoles; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2017 |
Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
Topics: Animals; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Neoplasms; Positron-Emission Tomography; Radioactive Tracers; Resorcinols; Spheroids, Cellular; Time Factors | 2009 |
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Immunohistochemistry; Isoxazoles; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Resorcinols; Tissue Distribution; Vascular Endothelial Growth Factor A; Zirconium | 2010 |
Synthesis and antitumor activity of 2,5-bis(3'-indolyl)-furans and 3,5-bis(3'-indolyl)-isoxazoles, nortopsentin analogues.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Furans; Humans; Indoles; Isoxazoles; Neoplasms | 2010 |
Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Topics: Benzoquinones; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Down-Regulation; Drug Evaluation, Preclinical; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lactams, Macrocyclic; Neoplasms; Pyrimidines; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols; Up-Regulation | 2010 |
A combined molecular modeling study on a series of pyrazole/isoxazole based human Hsp90α inhibitors.
Topics: Binding Sites; Computer Simulation; HSP90 Heat-Shock Proteins; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Isoxazoles; Models, Chemical; Models, Molecular; Molecular Conformation; Neoplasms; Protein Binding; Pyrazoles; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Synthesis and in vitro and in vivo anticancer activity of novel phenylmethylene bis-isoxazolo[4,5-b]azepines.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Line, Tumor; Chemistry, Pharmaceutical; Cisplatin; Drug Design; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Inhibitory Concentration 50; Isoxazoles; Magnetic Resonance Spectroscopy; Mass Spectrometry; Methanol; Mice; Models, Chemical; Neoplasms; Spectrophotometry, Infrared; Tetrazolium Salts; Thiazoles | 2012 |
Multi-component synthesis and in vitro and in vivo anticancer activity of novel arylmethylene bis-isoxazolo[4,5-b]pyridine-N-oxides.
Topics: Animals; Antineoplastic Agents; Cyclic N-Oxides; Drug Screening Assays, Antitumor; Female; Humans; In Vitro Techniques; Isoxazoles; Mice; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Synthesis, antimicrobial and anti-cancer activities of some new N-ethyl, N-benzyl and N-benzoyl-3-indolyl heterocycles.
Topics: Anti-Infective Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chalcones; Cyclohexanones; Disk Diffusion Antimicrobial Tests; Drug Design; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Indoles; Inhibitory Concentration 50; Isoxazoles; Neoplasms; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2012 |
The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Survival; Dogs; Female; Heart; Hemodynamics; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Microcirculation; Neoplasms; Neovascularization, Pathologic; Phenylalanine; Rabbits; Regional Blood Flow; Tubulin Modulators; Xenograft Model Antitumor Assays | 2012 |
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Isoxazoles; Neoplasms; Structure-Activity Relationship; Thiazoles; Triazoles | 2012 |
An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery.
Topics: Animals; Antineoplastic Agents; Benzamides; Biological Availability; Cell Proliferation; Cytidine Triphosphate; Diphenylamine; Drosophila melanogaster; Drug Screening Assays, Antitumor; Glutamine; Isoxazoles; Neoplasms; Pharmacogenetics; Pilot Projects | 2013 |
Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells.
Topics: Carcinoma; Cell Division; Cell Line, Tumor; Cell Membrane; Cisplatin; Clone Cells; Cyclic N-Oxides; Drug Resistance, Neoplasm; Fatty Acids; HeLa Cells; Humans; Isoxazoles; Membrane Fluidity; Membrane Lipids; Membrane Potentials; Membrane Proteins; Neoplasms; Potassium Channels; Pyrimidinones | 2004 |
Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.
Topics: Animals; Calcium; Cell Line; Cell Line, Tumor; Cell Movement; Cells, Cultured; Chemotaxis; Dose-Response Relationship, Drug; Fibroblasts; Glucose-6-Phosphate Isomerase; Glycoproteins; Isoxazoles; Lysophospholipids; Mice; Mice, Knockout; Mice, Transgenic; Microscopy, Fluorescence; Models, Biological; Multienzyme Complexes; Neoplasms; Phosphodiesterase I; Phosphoric Diester Hydrolases; Platelet-Derived Growth Factor; Propionates; Pyrophosphatases; rac1 GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction; rhoA GTP-Binding Protein; Signal Transduction; Skin; Time Factors | 2004 |
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Incidence; Isoxazoles; Lactones; Membrane Proteins; Meta-Analysis as Topic; Myocardial Infarction; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |
Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation.
Topics: Amino Acid Sequence; Anisoles; Antineoplastic Agents; Blotting, Western; Bromides; Cell Line, Tumor; Cell Membrane; Cell Movement; Chromatography, Affinity; Crk-Associated Substrate Protein; DNA, Complementary; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Isoxazoles; Models, Chemical; Molecular Chaperones; Molecular Sequence Data; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Binding; Protein Kinase C; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; RNA, Small Interfering; Time Factors; Transfection | 2005 |
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Endothelial Cells; Humans; Isoxazoles; Magnetic Resonance Imaging; Mice; Neoplasms; Neovascularization, Pathologic; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2006 |
Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.
Topics: Apoptosis; Catalysis; Cell Membrane; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Isoxazoles; Lymphocytes; Lysophospholipids; Models, Biological; Neoplasms; Permeability; Promoter Regions, Genetic; Propionates; Repressor Proteins | 2008 |
Acivicin: a new glutamine antagonist in clinical trials.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites; Dose-Response Relationship, Drug; Drug Evaluation; Female; Glutamine; Half-Life; Humans; Isoxazoles; Kinetics; Leukemia, Experimental; Liver Neoplasms, Experimental; Macaca mulatta; Male; Mice; Neoplasms; Oxazoles; Purines; Pyrimidines; Sarcoma, Experimental | 1984 |
Phase I evaluation of AT-125 single dose every three weeks.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Central Nervous System; Drug Administration Schedule; Drug Evaluation; Glutamine; Humans; Isoxazoles; Middle Aged; Neoplasms; Oxazoles | 1984 |
The analgesic effect of the GABA-agonist THIP in patients with chronic pain of malignant origin. A phase-1-2 study.
Topics: Adult; Aged; Analgesics; Analysis of Variance; Chronic Disease; Drug Evaluation; Female; Humans; Isoxazoles; Male; Middle Aged; Neoplasms; Oxazoles; Pain | 1983 |
Phase I and pharmacological study of acivicin by 24-hour continuous infusion.
Topics: Antimetabolites; Digestive System; Drug Evaluation; Humans; Infusions, Parenteral; Isoxazoles; Kinetics; Neoplasms; Nervous System; Oxazoles | 1982 |
Synthesis and cytotoxic action of 3,5-isoxazolidinediones and 2-isoxazolin-5-ones in murine and human tumors.
Topics: Animals; Antineoplastic Agents; Female; Humans; Isoxazoles; Mice; Molecular Structure; Neoplasms; Neoplasms, Experimental; Tumor Cells, Cultured | 1997 |
Signaling inhibitors in the clinic: new agents and new challenges.
Topics: Clinical Trials, Phase I as Topic; Growth Inhibitors; Humans; Isoxazoles; Leflunomide; Neoplasms; Phosphorylation; Receptor Protein-Tyrosine Kinases; Signal Transduction | 1999 |
Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Dipyridamole; Drug Evaluation; Humans; Isoxazoles; Leukocyte Count; Metabolic Clearance Rate; Neoplasms; Nucleosides | 1988 |